Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Alpibectir in Healthy Volunteers
NCT04654143Phase 1Completed
- Sponsor
- BioVersys AG
- Start
- Dec 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of alpibectir in Tuberculosis (TB), sponsored by BioVersys AG. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs), Number of participants with clinically significant abnormal findings in hematology parameters and 4 more. Started Dec 2020; status: completed.
02
Drugs
alpibectir
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04654143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04654143.